Our focus
A broad range of technologies for diagnosing and treating heart rhythm disorders.
A broad range of technologies for diagnosing and treating heart rhythm disorders.
Our EP portfolio is centered on delivering meaningful innovation for diagnosing and treating heart rhythm disorders, improving safety for patients, and improving efficiency for physicians.
Redefining heart care.
We’re dedicated to helping patients live longer, healthier lives with the RHYTHMIA HDx™ Mapping System, which provides physicians the ability to diagnose arrhythmias with greater efficiency, deliver targeted therapy and confidently achieve procedural endpoints in complex substrates. The DIRECTSENSE™ Technology adds support, measuring local impedance to provide insights into tissue characteristics and deepening the understanding of how lesions will form during ablation.
The future of ablation.
Advancements in treating atrial arrhythmias have given physicians more therapeutic options. The FARAPULSE™ Pulsed Field Ablation (PFA) System* is the pioneer of PFA – a novel, non-thermal method for cardiac ablation, which uses a process called irreversible electroporation designed to precisely and efficiently ablate cardiac tissue, while preserving adjacent tissue. The POLARx™ Cryoablation System* incorporates physician-driven design changes to provide increased procedural predictability in the treatment of paroxysmal atrial fibrillation.
Access better outcomes.
Our transseptal crossing platforms facilitate predictable and safe left heart access by using radiofrequency (RF) energy – a method shown to increase efficiency and improve the safety and efficacy of transseptal puncture during left heart procedures.i,ii,iii The VersaCross™ RF Transseptal Solution streamlines these crossing procedures and therapy delivery by eliminating potential wire and sheath exchanges, which may help mitigate risks during procedures.
i Journal of the American Heart Association, September 17, 2003. DOI: 10.1161/JAHA. 113000428
ii Winkle et al. Heart Rhythm, Vol. 8, Issue 9, 2022. DOI 10.1016/j.hrthm.2011.04.032
iii Inohara et al. J Interv Card Electrophys, 2021; in press (DOI: 10.1007/s10840-020-00931-7)
89%
Approximately 89% of all ablation cases worldwide are done with aid of mapping and navigation.3
400K
An estimated 400K electrophysiology ablation procedures were performed in the US in 2019.4
700K
More than 700K transseptal procedures are performed globally every year.5
Sources
*In the U.S., the FARAPULSE PFA System and the POLARx Cryoablation System are investigational devices and not available for sale.